Molecular Mechanisms in Malignant Lymphoma- Predict (MMML Predict)

The trial aims at the construction and validation of an accurate, affordable and simple prognostic tool to be used in everyday clinical practice, which allows the early and reliable identification of DLBCL patients who have a very high risk of treatment failure following R-CHOP/-like first-line therapy.

NCT Number	NCT06526065
Lead Sponsor	University Medical Center Goettingen Collaborators: Charite University, Berlin, Germany, Wuerzburg University Hospital, University Hospital Ulm, University of Leipzig, University Hospital Regensburg, University Hospital Freiburg, Robert Bosch Gesellschaft für Medizinische Forschung mbH (RBMF), University of Kiel, University Hospital, Essen
Conditions	DLBCL - Diffuse Large B Cell Lymphoma
Enrollment	500 participants
Start Date	2024-06-20
Primary Completion	2026-06-01 (estimated)
Study Completion	2029-06-01 (estimated)
Updated on ClinicalTrials.gov	2024-07-29